Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Terns Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Terns Pharmaceuticals, Inc.

TERN

Terns Pharmaceuticals, Inc.

About Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for serious diseases such as oncology and obesity. Its pipeline includes targeted treatments like BCR-ABL inhibitors for chronic myeloid leukemia and oral GLP-1 receptor agonists for weight management. The company emphasizes innovative mechanisms, strategic partnerships, and robust intellectual property to deliver improved clinical outcomes and address unmet medical needs.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Terns Pharmaceuticals, Inc.

1
1
Terns Pharmaceuticals, Inc. Terns Pharmaceuticals Reports $96.2 Million Net Loss for 2025, Merger with Merck Announced

Via official filing (AI summary) | 3 months ago | 0 comments

2
1
Terns Pharmaceuticals, Inc. Terns Pharmaceuticals Reports $24.6 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Terns Pharmaceuticals, Inc. Terns Pharmaceuticals Reports $48M Net Loss for First Half of 2025

Via official filing (AI summary) | 11 months ago | 0 comments

4
1
Terns Pharmaceuticals, Inc. Terns Pharmaceuticals Reports $23.9 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Terns Pharmaceuticals, Inc. Terns Pharmaceuticals Reports $88.85 Million Net Loss for 2024, Advances Drug Candidates

Via official filing (AI summary) | over 1 year ago | 0 comments

6
1
Terns Pharmaceuticals, Inc. Terns Pharmaceuticals Reports Significant Financial Growth and Milestones in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments